Second, we will increase the level of fiscal and financial support. We will implement support policies such as additional deductions for research and development costs and simple VAT collection on drugs for cancer and rare diseases. Guide financial institutions to innovate financial products, optimize supply chain financial services, support eligible enterprises to issue corporate credit bonds, and guide early investment to support scientific and technological innovation in the pharmaceutical industry. Encourage social capital to develop specialized medical venture capital funds and equity investment funds.
Third, we will standardize the order of market competition. Correct the improper trend in the field of pharmaceutical purchase and marketing, strictly regulate the registration management of pharmaceutical representatives and conduct norms, and crack down on illegal activities in related fields. We will strengthen law enforcement against unfair competition, and resolutely investigate and punish acts of unfair competition such as commercial bribery in the pharmaceutical sector. We will strengthen anti-monopoly law enforcement in the field of drugs in short supply and raw materials, and formulate and implement anti-monopoly guidelines in the field of raw materials. Remove local protection and market segmentation, and cancel unreasonable requirements for drug market access.
Fourth, we will strengthen the construction of human resources. Focus on training the industry shortage of drug discovery, clinical trial design, biological drug manufacturing and other professional talents and interdisciplinary talents. Through encouraging school-enterprise cooperation in running schools, commissioning training, building practical training bases, and connecting the growth channels of skilled workers, a number of "great craftsmen" in the pharmaceutical field are cultivated. Local governments and enterprises will be encouraged to introduce more high-level talents from overseas.
email:1583694102@qq.com
wang@kongjiangauto.com